Oncology Consultations®: Bridging Multidisciplinary Approaches and Evolving Data for Immunotherapy for NSCLC in Curative Settings
Oncology Consultations®: Bridging Multidisciplinary Approaches and Evolving Data for Immunotherapy for NSCLC in Curative Settings is organized by Physicians' Education Resource, LLC (PER).
Activity Overview:
The rapid pace of advances in lung cancer therapy, including stage I-III non–small cell lung cancer (NSCLC), has resulted in significant knowledge and competence gaps. With the increased use of immunotherapy in these settings, it is essential that physicians are able to recognize and manage immune-related adverse events. The latest data on immune checkpoint inhibition strategies are essential to translate clinical trial achievements into real-world practice changes that will optimize outcomes among patients with lung cancer.
This Oncology Consultations® online activity includes an expert discussion between faculty to provide a comprehensive update on where the most recent clinical trial evidence stands, discuss best practices with immuno-oncology strategies in non-metastatic NSCLC, and forecast future directions of care.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Determine the rationale to incorporate immune checkpoint inhibitors as consolidation therapy for unresectable stage III NSCLC and in perioperative therapy for early stage, resectable NSCLC
• Assess the clinical profile of immune checkpoint inhibitors evaluated in patients with unresectable stage III NSCLC and resectable stage I-III NSCLC
• Employ strategies to identify and manage adverse events related to immunotherapy-based regimens among patients with stage I-III NSCLC
• Translate expert recommendations and practice-changing data on immune checkpoint inhibitors in stage I-III NSCLC into individualized treatment plans, with a focus on multidisciplinary approaches involving thoracic surgeons, radiation oncologists, and medical oncologists
Additional details will be posted as soon as information is available.